Literature DB >> 15764090

Unoprostone isopropyl rescues retinal progenitor cells from apoptosis in vitro.

Hirokazu Mukuno1, Makoto Nakamura, Akiyasu Kanamori, Azusa Nagai, Akira Negi, Gail Seigel.   

Abstract

PURPOSE: Unoprostone isopropyl is an ocular hypotensive that was originally produced as a prostaglandin F2alpha analogue and is eventually recognized as a synthetic docosanoid. The compound is recently suggested to have potent neuroprotective ability in the retina. The purpose of this study is to test whether and how the biologically active metabolites of unoprostone isopropyl rescue retinal neuro-glial progenitor cells from apoptosis.
METHODS: R28 cells were deprived of serum for 24 hr with or without varying concentrations of unoprostone metabolite M1 or M2 or vehicle in the presence or absence of specific inhibitors against several types of signal transduction proteins. Immunocytochemistry against activated caspase-3 with Hoechst nuclear staining was performed.
RESULTS: Up to 15%of R28 cells became pyknotic and activated caspase-3 immunoreactive after 24-hr serum withdrawal. M1, but not M2, significantly reduced apoptotic cells in a dose-dependent fashion with a maximal effect at 100 microM (p < .0001). LY294002, the phosphatidylinositol 3-OH kinase (PI3K) inhibitor, and KT5823, the protein kinase G (PKG) inhibitor, reversed the antiapoptotic effect of M1.
CONCLUSIONS: The unoprostone metabolite M1 protects retinal neuro-glial progenitor R28 cells from apoptosis induced by serum deprivation via the PI3K and PKG pathways.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15764090     DOI: 10.1080/02713680490889465

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  9 in total

1.  Regeneration of optic nerve fibers with unoprostone, a prostaglandin-related antiglaucoma drug, in adult cats.

Authors:  Hiroe Sagawa; Hiroko Terasaki; Keiko Nakanishi; Yoshihito Tokita; Masami Watanabe
Journal:  Jpn J Ophthalmol       Date:  2013-10-16       Impact factor: 2.447

Review 2.  Endothelin antagonism as an active principle for glaucoma therapy.

Authors:  Rita Rosenthal; Michael Fromm
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

Review 3.  Neuroaxonal and cellular damage/protection by prostanoid receptor ligands, fatty acid derivatives and associated enzyme inhibitors.

Authors:  Najam A Sharif
Journal:  Neural Regen Res       Date:  2023-01       Impact factor: 6.058

4.  Tafluprost protects rat retinal ganglion cells from apoptosis in vitro and in vivo.

Authors:  Akiyasu Kanamori; Maiko Naka; Masahide Fukuda; Makoto Nakamura; Akira Negi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2009-06-24       Impact factor: 3.117

5.  Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study.

Authors:  Shuichi Yamamoto; Takeshi Sugawara; Akira Murakami; Mitsuru Nakazawa; Nobuhisa Nao-I; Shigeki Machida; Yuko Wada; Yukihiko Mashima; Yozo Myake
Journal:  Ophthalmol Ther       Date:  2012-09-06

6.  Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration.

Authors:  Chieko Shiragami; Masahiro Miyake; Atsushi Fujiwara; Yuki Morizane; Akitaka Tsujikawa; Ayana Yamashita; Fumio Shiraga
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

Review 7.  Looking into the Eyes-In Vitro Models for Ocular Research.

Authors:  Krystyna Lieto; Rafał Skopek; Aneta Lewicka; Marta Stelmasiak; Emilia Klimaszewska; Arthur Zelent; Łukasz Szymański; Sławomir Lewicki
Journal:  Int J Mol Sci       Date:  2022-08-15       Impact factor: 6.208

Review 8.  An evidence-based review of unoprostone isopropyl ophthalmic solution 0.15% for glaucoma: place in therapy.

Authors:  Derrick S Fung; Jess T Whitson
Journal:  Clin Ophthalmol       Date:  2014-03-10

Review 9.  Review: R28 retinal precursor cells: the first 20 years.

Authors:  Gail M Seigel
Journal:  Mol Vis       Date:  2014-03-14       Impact factor: 2.367

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.